| Autor: |
Keiji, Okinaka, Yukihiro, Akeda, Yoshihiro, Inamoto, Shigeo, Fuji, Ayumu, Ito, Takashi, Tanaka, Saiko, Kurosawa, Sung-Won, Kim, Ryuji, Tanosaki, Takuya, Yamashita, Chikako, Ohwada, Keiji, Kurata, Takeshi, Mori, Masahiro, Onozawa, Kuniko, Takano, Hiroki, Yokoyama, Katsuyoshi, Koh, Koji, Nagafuji, Kazutaka, Nakayama, Toru, Sakura, Tsutomu, Takahashi, Kazunori, Oishi, Takahiro, Fukuda |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Clinical Microbiology and Infection. 29:482-489 |
| ISSN: |
1198-743X |
| Popis: |
This multicentre, phase 2, randomized, controlled study of allogeneic haematopoietic stem cell transplantation (allo-HSCT) recipients compared the immunogenicity of two anti-pneumococcal vaccine regimens: four doses of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) (3+1+1 experimental group), and three doses of PCV13 followed by PPSV23 (3+0+1 group).Allo-HSCT recipients without active graft-versus-host disease at enrolment were eligible. The primary endpoint was the IgG response rate (≥0.20 mg/mL) for all eight measured serotypes at 5 months after the PPSV23 booster.Seventy-two recipients were randomized, and seventy recipients who received over one PCV13 dose were analysed. The mean ages were 47.2 years (standard deviation, 14.4) in the 3+1+1 group (n = 35) and 49.0 years (standard deviation, 14.3) in the 3+0+1 group (n = 35). There was no significant difference in the overall IgG response rate at 5 months after the PPSV23 booster between the 3+1+1 and 3+0+1 groups (100% (26/26) vs. 93% (27/29), respectively, relative risk (RR): 1.07; 95% confidence interval (CI): 0.97-1.19). This rate was high immediately before the PPSV23 booster in the 3+1+1 group (100% (26/26) compared with 81% (21/26), respectively, RR: 1.24; 95% CI: 1.03-1.49), but this difference disappeared 1 month after the PPSV23 booster (100% (26/26) vs. 97% (28/29), respectively, RR: 1.04; 95% CI; 0.97-1.11). No serious adverse events leading to study dropout occurred.We were not able to determine the efficacy of the experimental arm based on the IgG response rate at 5 months after the PPSV23 booster in allo-HSCT recipients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
